Preclinical Testing of a New Dry Powder Aerosol Synthetic Lung Surfactant Formulation and Device Combination for the Treatment of Neonatal Respiratory Distress Syndrome.

J Aerosol Med Pulm Drug Deliv · 2025 · PMC12433280 · PMID 40272931

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Furthermore, the D3-MSD2 aerosol group demonstrated an increasing trend in compliance through the final hour of the experiment that continued to the 3.5-hour final time point.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.